Sort
10,766 grants matching “checkpoint inhibitor”
Mesenchymal Cell Dysfunction in Fibroproliferative Lung Disease
$510,000Paul Wesley Noble · Cedars-Sinai Medical Center · P01 · FY2022 · HL
Mesenchymal Cell Dysfunction in Fibroproliferative Lung Disease
$510,000Paul Wesley Noble · Cedars-Sinai Medical Center · P01 · FY2021 · HL
Mesenchymal Cell Dysfunction in Fibroproliferative Lung Disease
$510,000Paul Wesley Noble · Cedars-Sinai Medical Center · P01 · FY2019 · HL
Plasmonic nanoparticle-mediated immunotherapy to treat metastatic cancer
$509,972Tuan Vo-Dinh · Duke University · R01 · FY2019 · EB
Radioprotective effect of p53 against oral mucositis
$509,544Chang-Lung Lee · Duke University · R01 · FY2025 · DE
The c-Rel Checkpoint for Immunosuppression and Immunotherapy
$509,524Youhai H Chen · University Of Pennsylvania · R01 · FY2020 · AI
Defining the role of mitochondrial injury in MEK inhibitor cardiotoxicity
$509,288Brian C Jensen · Univ Of North Carolina Chapel Hill · R01 · FY2024 · HL
Small molecule inhibitors as a new approach to study human RAD51 recombinase
$509,286Alexander V Mazin · Drexel University · R01 · FY2017 · CA
Small molecule inhibitors as a new approach to study human RAD51 recombinase
$509,286Alexander V Mazin · Drexel University · R01 · FY2016 · CA
Role of PI3Kgamma in Tumor Progression and Metastasis
$509,078Judith A. Varner · University Of California, San Diego · R01 · FY2024 · CA
Novel DNA damage response therapeutics targeting replication protein A
$509,008John J Turchi · Indiana University Indianapolis · R01 · FY2021 · CA
Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment
$508,990Jianjun Gao · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Project 1: Overcoming therapeutic resistance in pancreatic cancer through epigenetic reprogramming
$508,896Ronald M. Evans · Salk Institute For Biological Studies · P01 · FY2023 · CA
Project 1: Overcoming therapeutic resistance in pancreatic cancer through epigenetic reprogramming
$508,895Ronald M. Evans · Salk Institute For Biological Studies · P01 · FY2025 · CA
Molecular Mechanisms of Bladder Cancer Immunometabolism
$508,855Liuqing Yang · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
The c-Rel Checkpoint for Immunosuppression and Immunotherapy
$508,853Warren S Pear · University Of Pennsylvania · R01 · FY2021 · AI
In vivo imaging of mitochondria structure and function in therapy resistant lung tumors
$508,739David B Shackelford · University Of California Los Angeles · R01 · FY2024 · CA
The role of the mycobiome in cancer
$508,693Iliyan Dimitrov Iliev · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
The role of the mycobiome in cancer
$508,693Iliyan Dimitrov Iliev · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA
Proteomic determinants of response to checkpoint blockade in malignant pleuralmesothelioma
$508,688Bryan Michael Burt · Baylor College Of Medicine · R37 · FY2022 · CA
Clinical protocols for the treatment of gastrointestinal cancer
$508,487Tim Greten · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy
$508,324Yunyan Jennifer Jennifer Zhang · Duke University · R01 · FY2024 · CA
Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer
$508,157Raymond B Birge · Rbhs-New Jersey Medical School · R01 · FY2022 · CA
Project 1: Nanotherapies for Vemurafenib Resistant Melanoma
$508,105Leaf Huang · Univ Of North Carolina Chapel Hill · U54 · FY2017 · CA
Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate Cancer
$507,942Akash Patnaik · University Of Chicago · R01 · FY2024 · CA